ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Celastrol Inhibits the Proliferation and Induces Apoptosis of Colorectal Cancer Cells via Downregulating NF-κB/COX-2 Signaling Pathways

Zhang, Hua; Zhao, Xiaojin; Shang, Fajun; Sun, Huan; Zheng, Xu; Zhu, Jiabin*1
Anti-Cancer Agents in Medicinal Chemistry2022DOI: 10.2174/1871520611666211103103530
4被引7阅读
引用收藏
分享

摘要

Background: Colorectal cancer (CRC) is the third-ranked malignant tumor in the world that contributes to the death of a major population of the world. Celastrol, a bioactive natural product isolated from the medicinal plant Tripterygium wilfordii Hook F, has been proved to be an effective anti-tumor inhibitor for multiple tumors. @@@ Objective: To reveal the therapeutic effect and underlying mechanisms of celastrol on CRC cells. @@@ Methods: CCK-8 and clonogenic assay were used to analyze the cell proliferation in CRC cells. Flow cytometry analysis was conducted to assess the cell cycle and cell apoptosis. Wound-healing and cell invasion assay were used to evaluate the migrating and invasion capability of CRC cells. The potential antitumor mechanism of celastrol was investigated by qPCR, western blot, and confocal immunofluorescence analyses. @@@ Results: Celastrol effectively inhibited CRC cell proliferation by activating cat ase-dependent cell apoptosis and facilitating G1 cell cycle arrest in a dose-dependent manner, as well as cell migration and invasion by downregulating the MMP2 and MMP9. Mechanistic protein expression revealed that celastrol suppressed the expression of COX-2 by inhibiting the phosphorylation of NF-kappa B p65 and subsequently leading to cytoplasmic retention of p65 protein, thereby inhibiting its nuclear translocation and transcription activities. @@@ Conclusion: These findings indicate that celastrol is an effective inhibitor for CRC, regulating the NF-kappa B/COX-2 pathway, leading to the inhibition of cell proliferation characterized by cell cycle arrest and caspase-dependent apoptosis, providing a potential alternative therapeutic agent for CRC patients.

学科与关键词

关键词
Colorectal cancercelastrolcell proliferationapoptosisnuclear factor-kappa Bcyclooxygenase-2
相关
加载中…
  • Quantitative chemical proteomics reveals anti-cancer targets of Celastrol in HCT116 human colon cancer cells
    Zhang, Xing; Zhou, Jing; Zhu, Yongping; Wong, Yin Kwan; Liu, Dandan; Gao, Peng; Lin, Qingsong; Zhang, Jianbin*; Chen, Xiao*; Wang, Jigang*PHYTOMEDICINE, 2022, 101: 154096.被引 6
  • Identifying the Effect of Celastrol Against Ovarian Cancer With Network Pharmacology and In Vitro Experiments
    Wang, Xuan; Liu, Qiong; Wu, Sisi; Xu, Nana; Li, Hua*; Feng, Aihua*Frontiers in Pharmacology, 2022, 13: 739478.被引 5
  • Targeting OPA1-Mediated Mitochondrial Fusion Contributed to Celastrol's Anti-Tumor Angiogenesis Effect
    Li, Gaofu; Zhou, Lei; Deng, Huifang; Huang, Congshu; Wang, Ningning; Yue, Lanxin; Zhang, Pengfei; Zhou, Yongqiang; Zhou, Wei*; Gao, Yue*Pharmaceutics, 2023, 15(1): 48.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Anti-Cancer Agents in Medicinal Chemistry
发表日期
2022
卷期
第 22 卷, 第 10 期
页码
1921-1932
DOI
10.2174/1871520611666211103103530
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
Health Commission of Hubei Province Science Research Project [WJ2019H544, WJ2019H557]; Three Gorges University Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy [2019KZL07]; Yichang Science and Technology Bureau [A20-2-046]

作者

  • Z

    Zhang, Hua (第一作者)

    china three gorges univ

  • Z

    Zhao, Xiaojin

    china three gorges univ

查看全部 6 位作者收起作者
  • S

    Shang, Fajun

    china three gorges univ

  • S

    Sun, Huan

    china three gorges univ

  • Z

    Zheng, Xu

    china three gorges univ

  • Z

    Zhu, Jiabin (通讯)

    china three gorges univ · 1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417